The invention discloses the application of the ASMT / CYP1A1 molecular signature in predicting the clinical prognosis or immune characteristics of solid tumors. The inventors studied the transcriptome and genome data of 6,658 tumor samples from 14 kinds of solid tumors, and conducted a large-scale bioinformatics analysis, confirming that the ratio of ASMT / CYP1A1 in different solid tumors is related to the clinical prognosis and tumor mutation level of patients. , Tumor neoantigen load relationship. Among them, the clinical prognosis of cervical cancer, gastric cancer, and melanin patients in the High Index group was more impressive. The results of multivariate analysis showed that ASMT / CYP1A1 was an independent predictor of clinical prognosis in cancer patients; in addition, in colorectal cancer, head and neck squamous Among patients with cancer, kidney cancer, liver cancer, prostate cancer, and melanoma, although the prognosis of patients in the Low Index group is poor, there are more mutation loads and / or tumor neoantigens, suggesting that patients in this group are more likely to benefit from immunotherapy. benefit.